One company posts rapid revenue growth but remains unprofitable, while the other boasts global scale and steady cash flow.

Pfizer (NYSE:PFE | PFE Price Prediction) trades at $25.62, pays a 6.7% dividend yield, and just posted five straight ...

Pfizer (NYSE:PFE | PFE Price Prediction) is in the middle of its biggest reinvention in a generation, leaning on the Seagen ...

Pfizer stock may not be cheap enough to buy yet, but it's certainly too cheap to sell.

Hympavzi is approved for routine prophylaxis to prevent bleeding episodes in US patients six years and above.

By Maggie Fick, Bhanvi Satija and Patricia Weiss LONDON/FRANKFURT, June 10 (Reuters) - Pfizer is reviewing the timing and ...

The biotech company doesn’t have any obesity drugs on the market. Here’s how it plans to change that, and become an industry ...

The court’s first ruling recognizing a Pfizer vaccine death from TTS may widen the path to government compensation for ...

Chai Discovery is working with major drugmakers to use its latest antibody AI model to find new therapies. Now it’s in talks ...

Pfizer is paying Innovent $650 million upfront to partner on cancer drug development, following Bristol Myers Squibb by ...

By Michael Erman NEW YORK, June 6 (Reuters) - Pfizer presented data on Saturday that showed a monthly dose of an experimental ...

US pharmaceutical giant Pfizer has pulled out of a meeting with German Chancellor Friedrich Merz over plans to reform the ...